Yaqin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yaqin Wang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Wei Dai
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
11 shared publications - Xing Wei
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
11 shared publications - Qiuling Shi
School of Public Health, Chongqing Medical University, Chongqing, People’s Republic of China
10 shared publications - Jia Liao
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
9 shared publications - Qiang Li
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
8 shared publications - Yangjun Liu
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
8 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Patient perspectives on electronic patient-reported outcome-based symptom management after lung cancer surgery: a qualitative study
Background: Patients frequently experience severe symptoms after lung cancer surgery. Symptom management using electronic patient-reported outcomes (ePRO) can improve postoperative symptom burden, enhance functional status, and reduce complications. This qualitative study aimed to explore patient perspectives on ePRO-based symptom management. Methodology: Patients in a multicentre, randomised controlled trial (CN-PRO-Lung 2) conducted in China were asked to participate in qualitative interviews. In the trial, patients with lung cancer were randomly assigned in a 1:1 ratio to receive postoperative symptom management based on ePRO or usual care. To explore perspectives on the model, semi-structured interviews were conducted with 20 patients in the ePRO group. Data were analysed using descriptive and thematic analyses. Results: The median age of patients was 53.5 years (range: 28–73 years), with 55% being female. Two major themes emerged from the qualitative interviews: patient acceptance and patient-derived recommendations. Patient acceptance included four subthemes: patient satisfaction, daily life disruption and burden, postoperative recovery assistance, and long-term implementation needs. Patients were highly satisfied with the ePRO model and felt it did not increase their burden. They also found it beneficial for recovery and recommended long-term implementation. Patient-derived recommendations included two subthemes: enhancing the ePRO model and improving the system. Patients emphasised the importance of timely doctor feedback, a user-friendly interface, recognisable app icons, and additional self-reporting sections to increase engagement and efficiency. Conclusions: ePRO-based symptom management seems to be acceptable for patients who underwent lung cancer surgery. Future research should focus on optimising the ePRO model and system to better meet patient needs and facilitate its clinical implementation.
- 19 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessPatient perspectives on electronic patient-reported outcome-based symptom management after lung cancer surgery: a qualitative study
Background: Patients frequently experience severe symptoms after lung cancer surgery. Symptom management using electronic patient-reported outcomes (ePRO) can improve postoperative symptom burden, enhance functional status, and reduce complications. This qualitative study aimed to explore patient perspectives on ePRO-based symptom management. Methodology: Patients in a multicentre, randomised controlled trial (CN-PRO-Lung 2) conducted in China were asked to participate in qualitative interviews. In the trial, patients with lung cancer were randomly assigned in a 1:1 ratio to receive postoperative symptom management based on ePRO or usual care. To explore perspectives on the model, semi-structured interviews were conducted with 20 patients in the ePRO group. Data were analysed using descriptive and thematic analyses. Results: The median age of patients was 53.5 years (range: 28–73 years), with 55% being female. Two major themes emerged from the qualitative interviews: patient acceptance and patient-derived recommendations. Patient acceptance included four subthemes: patient satisfaction, daily life disruption and burden, postoperative recovery assistance, and long-term implementation needs. Patients were highly satisfied with the ePRO model and felt it did not increase their burden. They also found it beneficial for recovery and recommended long-term implementation. Patient-derived recommendations included two subthemes: enhancing the ePRO model and improving the system. Patients emphasised the importance of timely doctor feedback, a user-friendly interface, recognisable app icons, and additional self-reporting sections to increase engagement and efficiency. Conclusions: ePRO-based symptom management seems to be acceptable for patients who underwent lung cancer surgery. Future research should focus on optimising the ePRO model and system to better meet patient needs and facilitate its clinical implementation.
- 10 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4288-4300
Long-Term Patient-Reported Outcomes after Multiport Robot-Assisted Surgery versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
The purpose of this study was to compare patient-reported outcomes (PROs) and perioperative clinical outcomes during 1 year post surgery between robot-assi
- 10 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4288-4300
Long-Term Patient-Reported Outcomes after Multiport Robot-Assisted Surgery versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
The purpose of this study was to compare patient-reported outcomes (PROs) and perioperative clinical outcomes during 1 year post surgery between robot-assi
- 9 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4360-4361
ASO Visual Abstract: Long-Term Patient-Reported Outcomes After Multiport Robot-Assisted Surgery Versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
- 9 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4360-4361
ASO Visual Abstract: Long-Term Patient-Reported Outcomes After Multiport Robot-Assisted Surgery Versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
- Open Access
- 29 April 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-10
Sex-related differences in postoperative patient-reported outcomes among lung cancer patients: a multicenter cohort study
Studies on sex-related differences in post-lung cancer surgery symptoms are limited. Understanding these differences may provide insights into patient recovery. Therefore, we investigated sex-related differences in these symptoms and their underlying associated factors. We included patients aged ≥ 18 years undergoing surgery for lung cancer from a multicenter cohort study (CN-PRO-Lung 1) that focused on postoperative lung cancer symptoms trajectories. On a daily assessment schedule, we evaluated patients’ symptoms and their impact on functioning from the day before surgery until discharge using the MD Anderson Symptom Inventory–Lung Cancer module. We evaluated sex-related differences in symptom scores over time and identified influencing factors using linear mixed models. Of 372 eligible patients (196 men and 176 women;) symptoms were milder in men than in women for pain (estimate = 0.427, P = 0.021), fatigue (estimate = 1.071, P < 0.001), shortness of breath (estimate = 0.431, P = 0.021), lack of appetite (estimate = 0.728, P < 0.001), dry mouth (estimate = 0.438, P = 0.015), and constipation (estimate = 0.887, P < 0.001) during postoperative hospitalization (median: 7 days). Pain scores decreased over time in both sexes (estimate = -0.440 in men, P < 0.001; -0.510 in women, P < 0.001), while different factors were associated with increased pain in each group. In men, higher American Society of Anesthesiologists (ASA) classification (estimate = 0.430, P = 0.035), advanced pTNM stage (estimate = 0.550, P = 0.007), and having more than one chest drain (estimate = 0.690, P = 0.001) were associated with greater pain. In women, systematic lymph node dissection was associated with increased pain (estimate = 0.700, P = 0.033). Women reported a higher symptom burden than men in the early postoperative period after lung cancer surgery. Key factors associated with worse postoperative pain include higher ASA classification, advanced pTNM stage, and more than one chest tube in men and systematic lymph node dissection in women. NCT03341377
- 29 April 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-10
Open AccessSex-related differences in postoperative patient-reported outcomes among lung cancer patients: a multicenter cohort study
Studies on sex-related differences in post-lung cancer surgery symptoms are limited. Understanding these differences may provide insights into patient recovery. Therefore, we investigated sex-related differences in these symptoms and their underlying associated factors. We included patients aged ≥ 18 years undergoing surgery for lung cancer from a multicenter cohort study (CN-PRO-Lung 1) that focused on postoperative lung cancer symptoms trajectories. On a daily assessment schedule, we evaluated patients’ symptoms and their impact on functioning from the day before surgery until discharge using the MD Anderson Symptom Inventory–Lung Cancer module. We evaluated sex-related differences in symptom scores over time and identified influencing factors using linear mixed models. Of 372 eligible patients (196 men and 176 women;) symptoms were milder in men than in women for pain (estimate = 0.427, P = 0.021), fatigue (estimate = 1.071, P < 0.001), shortness of breath (estimate = 0.431, P = 0.021), lack of appetite (estimate = 0.728, P < 0.001), dry mouth (estimate = 0.438, P = 0.015), and constipation (estimate = 0.887, P < 0.001) during postoperative hospitalization (median: 7 days). Pain scores decreased over time in both sexes (estimate = -0.440 in men, P < 0.001; -0.510 in women, P < 0.001), while different factors were associated with increased pain in each group. In men, higher American Society of Anesthesiologists (ASA) classification (estimate = 0.430, P = 0.035), advanced pTNM stage (estimate = 0.550, P = 0.007), and having more than one chest drain (estimate = 0.690, P = 0.001) were associated with greater pain. In women, systematic lymph node dissection was associated with increased pain (estimate = 0.700, P = 0.033). Women reported a higher symptom burden than men in the early postoperative period after lung cancer surgery. Key factors associated with worse postoperative pain include higher ASA classification, advanced pTNM stage, and more than one chest tube in men and systematic lymph node dissection in women. NCT03341377
- Top Cited PapersOpen Access
- 4 April 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (18) , 2126-2131
Electronic Patient-Reported Outcome–Based Symptom Management Versus Usual Care After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized, Controlled Trial
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported superior symptom control of electronic patient-reported outcome (ePRO)–based symptom management after lung cancer surgery for up to 1 month postdischarge. Here, we present the long-term results (1-12 months) of this multicenter, randomized trial, where patients were assigned 1:1 to receive postoperative ePRO-based symptom management or usual care daily postsurgery, twice weekly postdischarge until 1 month, and at 3, 6, 9, and 12 months postdischarge. Long-term patient-reported outcomes were assessed with MD Anderson Symptom Inventory-Lung Cancer module. Per-protocol analyses were performed with 55 patients in the ePRO group and 57 in the usual care group. At 12 months postdischarge, the ePRO group reported significantly fewer symptom threshold events (any of the five target symptom scored ≥4; median [IQR], 0 [0-0] v 0 [0-1]; P = .040) than the usual care group. From 1 to 12 months postdischarge, the ePRO group consistently reported significantly lower composite scores for physical interference (estimate, –0.86 [95% CI, –1.32 to –0.39]) and affective interference (estimate, –0.70 [95% CI, –1.14 to –0.26]). Early intensive ePRO-based symptom management after lung cancer surgery reduced symptom burden and improved functional status for up to 1 year postdischarge, supporting its integration into standard care.
- 4 April 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (18) , 2126-2131
Top Cited PapersOpen AccessElectronic Patient-Reported Outcome–Based Symptom Management Versus Usual Care After Lung Cancer Surgery: Long-Term Results of a Multicenter, Randomized, Controlled Trial
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported superior symptom control of electronic patient-reported outcome (ePRO)–based symptom management after lung cancer surgery for up to 1 month postdischarge. Here, we present the long-term results (1-12 months) of this multicenter, randomized trial, where patients were assigned 1:1 to receive postoperative ePRO-based symptom management or usual care daily postsurgery, twice weekly postdischarge until 1 month, and at 3, 6, 9, and 12 months postdischarge. Long-term patient-reported outcomes were assessed with MD Anderson Symptom Inventory-Lung Cancer module. Per-protocol analyses were performed with 55 patients in the ePRO group and 57 in the usual care group. At 12 months postdischarge, the ePRO group reported significantly fewer symptom threshold events (any of the five target symptom scored ≥4; median [IQR], 0 [0-0] v 0 [0-1]; P = .040) than the usual care group. From 1 to 12 months postdischarge, the ePRO group consistently reported significantly lower composite scores for physical interference (estimate, –0.86 [95% CI, –1.32 to –0.39]) and affective interference (estimate, –0.70 [95% CI, –1.14 to –0.26]). Early intensive ePRO-based symptom management after lung cancer surgery reduced symptom burden and improved functional status for up to 1 year postdischarge, supporting its integration into standard care.
- Open Access
Protocol of an iterative qualitative study to develop a molecular testing decision aid for shared decision-making in patients with lung cancer after surgery
Introduction Although molecular testing is crucial for many patients with lung cancer, the decision to carry out molecular testing is not easy to make in actual clinical scenarios. Using a specific decision aid (DA) to conduct shared decision-making (SDM) may help ameliorate this problem. However, no DA currently exists for lung cancer molecular testing (DA_LCMT). We aim to develop an evidence-based, iteratively refined DA, which may facilitate SDM and improve the quality of SDM. Methods and analysis After considering the Ottawa Decision Support Framework, International Patient Decision Aid Standards and Food and Drug Administration guidance about methods to identify what is important to patients, semistructured interviews with qualitative research methods will be used to generate the decision-making needs of patients with lung cancer diagnosed with lung adenocarcinoma by intraoperative frozen pathological sections. Input will be provided by patients and other stakeholders, including thoracic surgeons, nurses, hospital administrators, molecular testing company staff and insurance company staff. Then, a modified Delphi method will be used to develop the DA_LCMT V.1.0 (DA_LCMT 1.0). Structured interviews with qualitative research methods will be used in the cognitive debriefing (alpha tests) and field testing (beta tests) to revise and improve the DA_LCMT from version 1.0 to the final version, version 3.0. Descriptive statistics will be used to summarise the baseline characteristics of the patients and other stakeholders. Qualitative data will be analysed using the three steps of grounded theory: generate a codebook, update the codebook and create a comprehensive list of related items. Ethics and dissemination Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital approved this study. This protocol is based on the latest version 1.0, dated 31 October 2021. The study was also approved by the Ethics Committees of The Third People’s Hospital of Chengdu, Zigong First People’s Hospital and Jiangyou People’s Hospital. The results of this study will be presented at medical conferences and published in peer-reviewed journals. Trial registration number NCT05191485.
Open AccessProtocol of an iterative qualitative study to develop a molecular testing decision aid for shared decision-making in patients with lung cancer after surgery
Introduction Although molecular testing is crucial for many patients with lung cancer, the decision to carry out molecular testing is not easy to make in actual clinical scenarios. Using a specific decision aid (DA) to conduct shared decision-making (SDM) may help ameliorate this problem. However, no DA currently exists for lung cancer molecular testing (DA_LCMT). We aim to develop an evidence-based, iteratively refined DA, which may facilitate SDM and improve the quality of SDM. Methods and analysis After considering the Ottawa Decision Support Framework, International Patient Decision Aid Standards and Food and Drug Administration guidance about methods to identify what is important to patients, semistructured interviews with qualitative research methods will be used to generate the decision-making needs of patients with lung cancer diagnosed with lung adenocarcinoma by intraoperative frozen pathological sections. Input will be provided by patients and other stakeholders, including thoracic surgeons, nurses, hospital administrators, molecular testing company staff and insurance company staff. Then, a modified Delphi method will be used to develop the DA_LCMT V.1.0 (DA_LCMT 1.0). Structured interviews with qualitative research methods will be used in the cognitive debriefing (alpha tests) and field testing (beta tests) to revise and improve the DA_LCMT from version 1.0 to the final version, version 3.0. Descriptive statistics will be used to summarise the baseline characteristics of the patients and other stakeholders. Qualitative data will be analysed using the three steps of grounded theory: generate a codebook, update the codebook and create a comprehensive list of related items. Ethics and dissemination Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital approved this study. This protocol is based on the latest version 1.0, dated 31 October 2021. The study was also approved by the Ethics Committees of The Third People’s Hospital of Chengdu, Zigong First People’s Hospital and Jiangyou People’s Hospital. The results of this study will be presented at medical conferences and published in peer-reviewed journals. Trial registration number NCT05191485.
- Open Access
- 3 September 2022
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 17 (1) , 1-8
Profiling symptom burden and its influencing factors at discharge for patients undergoing lung cancer surgery: a cross-sectional analysis
Background: Following lung cancer surgery, patients often experience severe symptoms which are not properly assessed at discharge. The aim of this study was to identify the clinical presentation at discharge and the influencing factors of postoperative symptoms in patients who have undergone lung cancer surgery. Methods: This cross-sectional study analysed data from patients who participated in a prospective cohort study that enrolled patients who underwent lung cancer surgery at six tertiary hospitals in the People’s Republic of China, from November 2017 to January 2020. Patient symptoms at discharge were measured using the MD Anderson Symptom Inventory Lung Cancer module. The five core symptoms were defined according to ratings of moderate to severe symptoms (≥ 4 on a 0–10 scale). A multivariate linear regression model was used to identify the influencing factors of each symptom at discharge. Results: Among the 366 participants, 51.9% were male and the mean (SD) age was 55.81 (10.43) years. At discharge, the core symptoms were cough (36.4%), pain (28.2%), disturbed sleep (26.3%), shortness of breath (25.8%), and fatigue (24.3%), and more than half of the participants (54.6%) had one to five of the core symptoms, with moderate to severe severity. A low annual income and the use of two chest tubes were significantly associated (P = 0.030 and 0.014, respectively) with higher mean scores of the core symptoms. Conclusion: Though clinically eligible for discharge, more than half of the participants had severe symptoms at discharge after lung cancer surgery. Special attention should be given to patients who have two chest tubes after surgery and those who have a low annual income.
- 3 September 2022
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 17 (1) , 1-8
Open AccessProfiling symptom burden and its influencing factors at discharge for patients undergoing lung cancer surgery: a cross-sectional analysis
Background: Following lung cancer surgery, patients often experience severe symptoms which are not properly assessed at discharge. The aim of this study was to identify the clinical presentation at discharge and the influencing factors of postoperative symptoms in patients who have undergone lung cancer surgery. Methods: This cross-sectional study analysed data from patients who participated in a prospective cohort study that enrolled patients who underwent lung cancer surgery at six tertiary hospitals in the People’s Republic of China, from November 2017 to January 2020. Patient symptoms at discharge were measured using the MD Anderson Symptom Inventory Lung Cancer module. The five core symptoms were defined according to ratings of moderate to severe symptoms (≥ 4 on a 0–10 scale). A multivariate linear regression model was used to identify the influencing factors of each symptom at discharge. Results: Among the 366 participants, 51.9% were male and the mean (SD) age was 55.81 (10.43) years. At discharge, the core symptoms were cough (36.4%), pain (28.2%), disturbed sleep (26.3%), shortness of breath (25.8%), and fatigue (24.3%), and more than half of the participants (54.6%) had one to five of the core symptoms, with moderate to severe severity. A low annual income and the use of two chest tubes were significantly associated (P = 0.030 and 0.014, respectively) with higher mean scores of the core symptoms. Conclusion: Though clinically eligible for discharge, more than half of the participants had severe symptoms at discharge after lung cancer surgery. Special attention should be given to patients who have two chest tubes after surgery and those who have a low annual income.
- Top Cited PapersOpen Access
- 20 March 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (9) , 988-996
Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial
PURPOSE: We aimed to evaluate the efficacy and feasibility of patient-reported outcome (PRO)-based symptom management in the early period after lung cancer surgery. METHODS: Before surgery, patients with clinically diagnosed lung cancer were randomly assigned 1:1 to receive postoperative PRO-based symptom management or usual care. All patients reported symptoms on MD Anderson Symptom Inventory-Lung Cancer presurgery, daily postsurgery, and twice a week after discharge for up to 4 weeks via an electronic PRO system. In the intervention group, treating surgeons responded to overthreshold electronic alerts driven by any of the five target symptom scores (score ≥ 4 on a 0-10 scale for pain, fatigue, disturbed sleep, shortness of breath, and coughing). The control group patients received usual care and no alerts were generated. The primary outcome was the number of symptom threshold events (any target symptom with a score of ≥ 4) at discharge. Per-protocol analyses were conducted. RESULTS: Of the 166 participants, 83 were randomly allocated to each group. At discharge, the intervention group reported fewer symptom threshold events than the control group (median [interquartile range], 0 [0-2] v 2 [0-3]; P = .007). At 4 weeks postdischarge, this difference was maintained between the intervention and control groups (median [interquartile range], 0 [0-0] v 0 [0-1]; P = .018). The intervention group had a lower complication rate than the control group (21.5% v 40.6%; P = .019). Surgeons spent a median of 3 minutes managing an alert. CONCLUSION: PRO-based symptom management after lung cancer surgery showed lower symptom burden and fewer complications than usual care for up to 4 weeks postdischarge.
- 20 March 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (9) , 988-996
Top Cited PapersOpen AccessPatient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial
PURPOSE: We aimed to evaluate the efficacy and feasibility of patient-reported outcome (PRO)-based symptom management in the early period after lung cancer surgery. METHODS: Before surgery, patients with clinically diagnosed lung cancer were randomly assigned 1:1 to receive postoperative PRO-based symptom management or usual care. All patients reported symptoms on MD Anderson Symptom Inventory-Lung Cancer presurgery, daily postsurgery, and twice a week after discharge for up to 4 weeks via an electronic PRO system. In the intervention group, treating surgeons responded to overthreshold electronic alerts driven by any of the five target symptom scores (score ≥ 4 on a 0-10 scale for pain, fatigue, disturbed sleep, shortness of breath, and coughing). The control group patients received usual care and no alerts were generated. The primary outcome was the number of symptom threshold events (any target symptom with a score of ≥ 4) at discharge. Per-protocol analyses were conducted. RESULTS: Of the 166 participants, 83 were randomly allocated to each group. At discharge, the intervention group reported fewer symptom threshold events than the control group (median [interquartile range], 0 [0-2] v 2 [0-3]; P = .007). At 4 weeks postdischarge, this difference was maintained between the intervention and control groups (median [interquartile range], 0 [0-0] v 0 [0-1]; P = .018). The intervention group had a lower complication rate than the control group (21.5% v 40.6%; P = .019). Surgeons spent a median of 3 minutes managing an alert. CONCLUSION: PRO-based symptom management after lung cancer surgery showed lower symptom burden and fewer complications than usual care for up to 4 weeks postdischarge.
- Open Access
- 10 November 2021
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 5 (1) , 1-9
Translation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer
Background: The latest European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 29 (QLQ-LC29) has been translated and validated in several languages but not yet in simplified Chinese. This study aimed to translate this questionnaire into simplified Chinese and adapt it for use in Chinese patients with lung cancer. Methods: The translation and adaptation process followed the EORTC translation procedure, and consisted of eight steps, namely, translation preparation, forward translations, reconciled translation, back translations, a back translation report, proofreading, pilot testing, and finalisation. The pilot testing included 10 patients with lung cancer. Results: We obtained the permission to perform the EORTC QLQ-LC29 translation work on November 17, 2020. Thereafter, it took 3 weeks to complete the forward translations, reconciled translation, and back translations. After several rounds of discussion with the EORTC Translation Unit, 19 items used the existing translations from the EORTC Item Library (a database of EORTC questionnaire items and their translations), and 10 items were translated from scratch. The 10 patients included in the pilot testing phase had a median age of 64 years (range 31–69 years); five were male, five had an educational level of high school or above, and six had undergone surgery. Eight items received comments from patients (six items by one patient alone and the other two items by three patients). No patients commented on the instructions or the format used for responses. After discussion with the EORTC Translation Unit, we modified the Chinese wording in item 50 to ensure that the meaning of “lifeless” was clear. No changes were made to the remaining items. Conclusions: The simplified Chinese version of the EORTC QLQ-LC29 is now available on the EORTC website. This translation may contribute to the application of the EORTC QLQ-LC29 scale in both research and clinical practice in the Chinese population with lung cancer. Further evaluation of the psychometric properties of the translated EORTC QLQ-LC29 is warranted.
- 10 November 2021
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 5 (1) , 1-9
Open AccessTranslation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer
Background: The latest European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 29 (QLQ-LC29) has been translated and validated in several languages but not yet in simplified Chinese. This study aimed to translate this questionnaire into simplified Chinese and adapt it for use in Chinese patients with lung cancer. Methods: The translation and adaptation process followed the EORTC translation procedure, and consisted of eight steps, namely, translation preparation, forward translations, reconciled translation, back translations, a back translation report, proofreading, pilot testing, and finalisation. The pilot testing included 10 patients with lung cancer. Results: We obtained the permission to perform the EORTC QLQ-LC29 translation work on November 17, 2020. Thereafter, it took 3 weeks to complete the forward translations, reconciled translation, and back translations. After several rounds of discussion with the EORTC Translation Unit, 19 items used the existing translations from the EORTC Item Library (a database of EORTC questionnaire items and their translations), and 10 items were translated from scratch. The 10 patients included in the pilot testing phase had a median age of 64 years (range 31–69 years); five were male, five had an educational level of high school or above, and six had undergone surgery. Eight items received comments from patients (six items by one patient alone and the other two items by three patients). No patients commented on the instructions or the format used for responses. After discussion with the EORTC Translation Unit, we modified the Chinese wording in item 50 to ensure that the meaning of “lifeless” was clear. No changes were made to the remaining items. Conclusions: The simplified Chinese version of the EORTC QLQ-LC29 is now available on the EORTC website. This translation may contribute to the application of the EORTC QLQ-LC29 scale in both research and clinical practice in the Chinese population with lung cancer. Further evaluation of the psychometric properties of the translated EORTC QLQ-LC29 is warranted.